38.80
Agios Pharmaceuticals Inc stock is traded at $38.80, with a volume of 722.57K.
It is up +1.57% in the last 24 hours and down -2.17% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$38.20
Open:
$38.25
24h Volume:
722.57K
Relative Volume:
1.00
Market Cap:
$2.25B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.4155
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+4.84%
1M Performance:
-2.17%
6M Performance:
+10.16%
1Y Performance:
-15.10%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AGIO
Agios Pharmaceuticals Inc
|
38.80 | 2.18B | 32.87M | 674.31M | -330.11M | 11.36 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-24-25 | Initiated | H.C. Wainwright | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Oct-10-24 | Resumed | Raymond James | Outperform |
Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
Feb-03-23 | Initiated | Piper Sandler | Overweight |
Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Dec-03-21 | Initiated | BofA Securities | Buy |
Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
Jul-01-21 | Initiated | Raymond James | Mkt Perform |
Jun-10-21 | Initiated | H.C. Wainwright | Buy |
Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-04-20 | Initiated | Barclays | Equal Weight |
Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
May-23-19 | Resumed | Goldman | Neutral |
Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
May-23-18 | Initiated | Citigroup | Buy |
Apr-11-18 | Reiterated | Credit Suisse | Outperform |
Feb-15-18 | Reiterated | Needham | Buy |
Feb-15-18 | Reiterated | SunTrust | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Aug-10-17 | Reiterated | Needham | Buy |
Aug-08-17 | Reiterated | SunTrust | Buy |
Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
Jun-26-17 | Downgrade | Janney | Buy → Neutral |
Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-24-16 | Initiated | Needham | Buy |
Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Can Agios Pharmaceuticals Inc. withstand a market correction2025 Sector Review & Consistent Growth Equity Picks - sundaytimes.kr
How to track smart money flows in Agios Pharmaceuticals Inc.Earnings Overview Report & Advanced Swing Trade Entry Plans - Newser
Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Performance Recap & Long-Term Safe Return Strategies - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyJuly 2025 Movers & AI Optimized Trade Strategies - Newser
Can Agios Pharmaceuticals Inc. generate free cash flowCEO Change & Weekly Sector Rotation Insights - thegnnews.com
Published on: 2025-08-13 06:00:50 - Newser
How institutional ownership impacts Agios Pharmaceuticals Inc. stockJuly 2025 Action & Weekly High Potential Alerts - Newser
Can Agios Pharmaceuticals Inc. Regain Lost Ground This QuarterMarket Entry and Exit Point Tips From Traders - 선데이타임즈
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors - Business Wire
Full technical analysis of Agios Pharmaceuticals Inc. stockLow Exposure Strategy with Sector Analysis - Newser
How Agios Pharmaceuticals Inc. stock performs during market volatilityMachine Learning Stock Price Forecast Tool - Newser
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios Pharmaceuticals Shares Plunge 23% Amid Safety Concerns - AInvest
TR | OpenAI4o Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $38 - 富途牛牛
Can a trend reversal in Agios Pharmaceuticals Inc. lead to recoveryChart Driven Entry Timing for Swing Trades - Newser
Agios Shares Fall 15% After Report of Deaths Among Pyrukynd Patients - MSN
TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada
Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com
Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech
Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating - 富途牛牛
Envestnet Asset Management Inc. Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛
SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns - Asianet Newsable
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times
Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan
Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru
Agios evaluating fourth Pyrukynd case after analyst report - TipRanks
Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks
Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com
Agios Pharmaceuticals Becomes Oversold (AGIO) - Nasdaq
Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest
Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha
Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada
How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News
Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News
What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News
What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News
What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News
What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest
Agios Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Smith Cynthia | Director |
Aug 11 '25 |
Option Exercise |
0.00 |
2,302 |
0 |
12,414 |
Goff Brian | Chief Executive Officer |
Aug 08 '25 |
Option Exercise |
0.00 |
22,691 |
0 |
134,613 |
Goff Brian | Chief Executive Officer |
Aug 08 '25 |
Sale |
36.67 |
11,085 |
406,487 |
123,528 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):